Adalimumab biosimilar - Alvotech
Alternative Names: ADALACIP; Adalimumab-EVA; adalimumab-ryvk; Ardalicip; AVT 02; AVT 02 - Alvotech; Ciptunec; HUKYNDRA; LIBMYRIS; SIMLANDI; SIMLANDITMLatest Information Update: 23 May 2024
At a glance
- Originator Alvotech
- Developer Alvotech; Bioventure; Fuji Pharmaceutical; JAMP Pharma; STADA Arzneimittel
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Monoclonal antibodies; Nootropics; Skin disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ankylosing spondylitis; Axial spondyloarthritis; Crohn's disease; Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis; Uveitis
- No development reported Autoimmune disorders